A new diploma program has been established to enhance the comprehensive care of multiple sclerosis patients by training healthcare professionals in developing personalized health pathways. Designed for medical and paramedical practitioners working in both hospital and community settings, the program emphasizes multidimensional patient assessment considering general, personal, professional, social, and psychological dimensions. The curriculum, integrated with the MS Resource and Coordination Center (CRC SEP) at Henri Mondor University Hospital and SINDEFI-SEP, covers fourteen core competency units delivered online, including MS neurology consultations, diagnostic follow-up, professional life management, disability compensation, therapeutic education, and care coordination. Graduates will possess the skills to construct and implement personalized health plans leveraging appropriate resources and stakeholders. The next cohort begins September 2026 through April 2027, with enrollment closing September 2026. Training fees are €1,330 plus €178 registration. Applications requiring CV, motivation letter, and diploma qualifications should be submitted to Fabienne Pelé at fabienne.pele@sindefi.org.

Multiple sclerosis is a chronic inflammatory neurological disorder affecting approximately 2.8 million people worldwide, where the immune system mistakenly attacks the protective sheath of nerve fibers in the central nervous system, disrupting communication between the brain and body. This causes diverse symptoms including coordination and balance disorders, movement difficulties, visual and cognitive impairments, often exacerbated by fatigue. The article introduces eye-tracking technology as a potential diagnostic tool, given that ocular movement circuits span multiple brain regions that may overlap with areas affected by MS. Current MS diagnosis relies on clinical evaluation, neurological examination, MRI imaging to visualize central nervous system lesions, and supplementary tests to exclude alternative causes, with clinicians adhering to revised McDonald criteria to standardize diagnosis. However, the article highlights a critical clinical concern: approximately 18 percent of MS diagnoses may be incorrect, with 50 percent of misdiagnosed patients retaining their false diagnosis for at least three years and 70 percent receiving disease-modifying treatments unnecessarily. The newsletter from neuroClues® emphasizes the importance of exploring eye-tracking technology to improve diagnostic accuracy and patient outcomes in MS management.

Multiple sclerosis treatment has undergone major transformations over the past three decades, evolving from initial platform molecules to high-efficacy therapies (HET), with disease-modifying treatments (DMT) now offering earlier, more targeted, and better-tolerated strategies. Understanding the mechanisms driving disability progression is essential for optimizing patient care. Three distinct mechanisms can lead to disability worsening: relapse-associated worsening (RAW), stemming from acute inflammation where controlling relapse risk is paramount; progression independent of relapse activity (PIRA), linked to compartmentalized central inflammation requiring Bruton tyrosine kinase inhibitors (BTKi), currently in development, for better targeting; and axonal degeneration resulting from the previous two phenomena. Three guiding principles have proven critical for reducing disability risk: treating as early as possible through timely diagnosis; prescribing high-efficacy therapy immediately; and maintaining treatment over the long term. This comprehensive approach reflects the evolution of MS management toward increasingly sophisticated and individualized therapeutic strategies designed to prevent progressive disability through early intervention and sustained disease control.

Multiple sclerosis is a chronic autoimmune inflammatory disease of the central nervous system characterized by distinct clinical presentations and evolving pathophysiology. Disability progression occurs through relapse-associated worsening, where repeated inflammatory episodes cause cumulative damage, and through progression independent of relapse activity, driven by compartmentalized microglial inflammation and secondary neurodegeneration. Prior to disease-modifying treatments, approximately half of patients required wheelchair assistance within fifteen to twenty years. Contemporary clinical outcomes have substantially improved through early diagnosis and initiation of high-efficacy treatments. The disease manifests in several distinct forms, including the most common relapsing-remitting presentation, characterized by focal relapses followed by complete or partial recovery within six months.

Stem cell therapy represents a revolutionary regenerative approach with variable success rates across different medical applications, from orthopedic pain relief to experimental neurological treatments. Recent scientific advances demonstrate significant progress in understanding treatment mechanisms and achieving evidence-based practices. Research reveals promising outcomes including improved functional recovery in neurological disorders and orthopedic injuries, alongside enhanced tissue regeneration. Simultaneously, studies have identified methods to mitigate adverse effects such as tumorigenesis and immune-mediated complications. These developments have refined safety protocols and patient selection criteria, enabling more personalized treatment approaches. Success rates in stem cell therapy are measured by patients achieving desired outcomes such as symptom reduction, disease remission, or improved quality of life, though efficacy and safety profiles continue to evolve as the field matures.

T- and B-cell depletion has emerged as a pivotal immunotherapeutic approach for managing autoimmune diseases by selectively eliminating autoreactive lymphocytes. T-cell depletion interrupts pathogenic activation cascades and aberrant immune interactions, while B-cell depletion suppresses antigen presentation and autoantibody generation. Modern depletion technologies, including monoclonal antibodies, engineered biologics, bispecific agents, and cellular therapies, deliver enhanced specificity with minimal off-target immunosuppression. Understanding lymphocyte reconstitution and compensatory immune mechanisms has refined therapeutic optimization, enabling precision-based interventions that achieve sustained disease control while maintaining targeted immunomodulation.

OFSEP operates an integrated digital infrastructure supporting multiple sclerosis research and clinical management across France. The EDMUS software serves as a computerized medical record system enabling neurologists to document and analyze patient data efficiently. The Shanoir platform provides secure web-based access for structuring, managing, and sharing neuroimaging data, with automated tools facilitating anonymized MRI transfers from hospital systems. TumoroteK manages biological samples across participating biobanks, creating a virtual centralized repository while maintaining anonymized data integrity. Together, these interconnected open-source systems enable comprehensive data collection, standardization, and collaborative research while ensuring patient privacy and clinical utility.

This 2026 epigenetic lexicon compiles 45 fundamental concepts spanning from DNA methylation to sirtuines, including TADs, X-inactivation, and epigenetic aging. Epigenetics, positioned at the intersection of genetics and cellular biology, examines mechanisms that modulate gene expression without altering DNA sequences. These mechanisms, such as methylation and histone modifications, function as molecular switches, influencing organismal development, environmental adaptation, and intergenerational trait transmission. Each term is explained accessibly yet precisely, accompanied by concrete examples and health implications. The lexicon serves as an essential reference guide for students, researchers, and life sciences enthusiasts seeking to understand how molecular processes like acetylation and RNA interference regulate gene activity and contribute to conditions ranging from cancer to neurodegenerative diseases, offering insights into cutting-edge epigenetic discoveries.

Une entreprise de biotechnologie basée à Boston a lancé le premier essai clinique chez l’homme d’une thérapie de reprogrammation cellulaire, marquant ainsi une étape importante dans la lutte contre le vieillissement cellulaire. Ce traitement, baptisé ER-100, cible la perte de vision liée à l’âge et le glaucome en reprogrammant les cellules vieillissantes pour leur redonner un état plus jeune grâce à une restauration épigénétique. Développée par Life Biosciences, société cofondée par le généticien David Sinclair, cette thérapie utilise un virus modifié pour introduire trois gènes soigneusement sélectionnés — OCT4, SOX2 et KLF4 — qui réinitialisent les horloges cellulaires. L’œil a été stratégiquement choisi comme premier terrain d’essai en raison de son isolement relatif par rapport au reste du corps, ce qui minimise les effets indésirables systémiques potentiels. Cette approche s’appuie sur les travaux pionniers du lauréat du prix Nobel Shinya Yamanaka et sur des études antérieures menées dans des laboratoires de Harvard, qui ont démontré une régénération neuronale et une restauration de la vision réussies chez des souris atteintes de glaucome.

Life Biosciences, a Boston-based biotechnology firm, has achieved a groundbreaking milestone by administering the first human treatment designed to reverse cellular aging. The therapy, designated ER-100, utilizes three proteins known as OSK factors to perform partial epigenetic reprogramming, effectively resetting cellular age and restoring function in damaged or aging cells. Specifically targeting optic neuropathies characterized by optic nerve damage, this gene therapy delivers genetic instructions that act as a cellular reset mechanism. Following successful trials in rodents and primates, the company has announced the treatment of the first human patient, representing the inaugural approved epigenetic restoration candidate in clinical trials and potentially the first demonstration of human cellular rejuvenation if successful.

Multiple sclerosis (MS) is a central nervous system inflammatory autoimmune disease resulting from the interaction between genetic susceptibility and environmental factors, particularly geographic and viral influences. The condition involves two distinct inflammatory mechanisms: acute peripheral inflammation characterized by demyelinating plaques disseminated throughout the central nervous system, which manifests as sudden disease relapses, and chronic compartmentalized inflammation described as a "slow-burning" process that drives progressive clinical deterioration and neurodegeneration with atrophy. Affecting approximately three million people globally, MS represents the leading cause of non-traumatic neurological disability in adults within industrialized countries, with France reporting nearly 116,000 recognized cases in 2022.

Life Biosciences announced on June 9, 2026, that the first patient received ER-100, an experimental gene therapy designed to reverse cellular aging. This phase 1 trial, FDA-approved in January, addresses two optic nerve conditions—open-angle glaucoma and anterior ischemic optic neuropathy—major causes of adult blindness for which no existing treatments can regenerate destroyed neurons. The therapy employs partial epigenetic reprogramming, injecting three transcription factors directly into the eye via gene therapy vector to reactivate dormant molecular mechanisms in adult cells, restoring damaged optic nerve cells to a younger functional state without regressing to stem cell stages that could trigger tumors. Building on Harvard geneticist David Sinclair's landmark 2020 research demonstrating this gene combination regenerates optic nerves and restores vision in aged and glaucomatous mice, Life Biosciences successfully reproduced results in primates without serious adverse effects. The eye provides a relatively controlled experimental environment, partially isolated from systemic circulation, limiting potential side effects.

La sclérose en plaques est une maladie auto-immune qui touche le cerveau et qu'on ne sait toujours pas vraiment guérir. La mise sur le marché d'un nouveau traitement vient d'être validée par les autorités sanitaires européennes.

Aging is a complex biological process involving progressive decline in physiological function, driven by accumulation of cellular and molecular damage across multiple levels. While researchers have identified key hallmarks of aging including genomic instability, telomere attrition, and mitochondrial dysfunction, clinical practice has traditionally relied on chronological age as the primary metric for understanding aging. However, chronological age oversimplifies this multifactorial phenomenon and fails to account for significant individual variations in the aging process. This reliance stems from the historical absence of reliable biomarkers and measurement methods. Consequently, chronological age serves as an imperfect proxy for functional capacity and health vulnerability, as individuals of the same age often exhibit markedly different physiological states and health outcomes. Understanding the causal mechanisms underlying aging requires moving beyond chronological age toward more sophisticated, personalized measures of biological aging.

I cannot provide a summary for this article because the content provided only shows a redirect page without the actual article text. To write an accurate and informative professional summary, I would need access to the full article content discussing the relationship between Epstein-Barr virus and multiple sclerosis. Please provide the complete article text, and I will be happy to create a comprehensive 100-word summary suitable for a professional intelligence platform.

Multiple sclerosis research is advancing significantly through new diagnostic methods and treatment approaches. Scientists are developing disease-modifying therapies and exploring experimental stem cell treatments to better manage inflammation, protect nerves, and repair myelin damage, particularly for progressive MS patients. Genetic research has revealed that specific gene variants can influence MS progression rates and disease severity. A recent 2023 study found that individuals carrying certain genetic markers required mobility assistance approximately 3.7 years earlier than those without these variants, suggesting genes play a crucial role in the brain's capacity to manage MS damage. Diagnosis continues to rely on MRI imaging, blood tests, and spinal fluid analysis. While stem cell therapy remains experimental and not yet widely available, ongoing research into genetic factors and innovative treatment modalities offers promising potential for improving patient outcomes and understanding disease mechanisms.

Researchers have developed a groundbreaking approach to reverse cellular aging by resetting the epigenetic clock through partial epigenetic reprogramming (PER). Unlike previous full reprogramming methods that transformed adult cells into blank slates but risked uncontrolled differentiation, PER rejuvenates aged cells while preserving their identity and function. This technique works by erasing epigenetic changes accumulated over time without compromising cellular characteristics. Life Biosciences is advancing this technology with ER-100, entering the first-in-human study for treating optic neuropathies. The therapeutic potential extends beyond vision restoration, promising broader clinical applications in addressing age-related cellular decline and potentially revolutionizing regenerative medicine.

Despite major advances in therapy for multiple sclerosis (MS) patients, substantial unmet needs remain, particularly regarding the prevention of disability progression and the treatment of progressive and aggressive forms of the disease. While early use of high-efficacy therapies has improved inflammatory disease control, their impact on long-term neurodegeneration is limited, and therapeutic options for progressive MS remain scarce. Autologous hematopoietic stem cell transplantation (AHSCT) has emerged as a highly effective escalation strategy for selected patients with aggressive, inflammatory MS.

Researchers from Yale School of Medicine have identified a genetically driven immunologic mechanism linking Epstein-Barr virus (EBV) infection to multiple sclerosis development. This collaborative study, involving international institutions, elucidates how genetic factors predispose individuals to MS through EBV-triggered immune responses. The findings represent a significant advancement in understanding the molecular basis of MS pathogenesis, potentially opening new therapeutic avenues for prevention and treatment. By establishing this mechanistic link between viral infection and autoimmune disease, the research contributes valuable insights into how environmental and genetic factors converge in neurological disease development.

This comprehensive review examines how innate immunity fundamentally regulates adaptive immune responses through multiple interconnected mechanisms. The authors elucidate three primary pathways: remodeling of antigen presentation and costimulation, cytokine-mediated T helper cell polarization, and metabolic-epigenetic programming associated with trained immunity. The framework identifies three critical regulatory dimensions of innate immune signaling: insufficient activation impairs pathogen control and adaptive priming, excessive persistent activation drives autoimmune inflammation, and type 2-biased signaling promotes allergic responses. By integrating molecular signaling, cell crosstalk, metabolic regulation, and epigenetic remodeling, this review provides a unified understanding of how innate immune dysfunction contributes to adaptive immune dysregulation in infection, autoimmunity, and allergic diseases, while identifying therapeutic targets including interferon pathways, inflammasomes, and metabolic programs.